Literature DB >> 20013267

Anti-TNF therapies: a comprehensive analysis of adverse effects associated with immunosuppression.

Victoria Connor1.   

Abstract

Knowledge and understanding about the immunosuppressive properties of anti-TNF therapies and the adverse effects these causes have advanced over the last 10 years since the first of these drugs was approved. These drugs work by inhibiting tumour necrosis factor (TNF) in the body, which plays an essential role in the immune response to invading pathogens. Anti-TNF drugs have therapeutic value because high levels of TNF are thought to be part of the pathophysiology of many chronic inflammatory disorders such as rheumatoid arthritis and Crohn's disease. Anti-TNF drugs are usually well-tolerated, however, there have been reports of many potentially serious adverse effects. This article will comprehensively analyse these adverse effects; the incidence, symptoms and mechanisms will be discussed. In addition, the contraindications of this class of drugs will be explored and the detection and prevention methods that should be put in place by health care professionals who treat patients on these drugs will be described.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20013267     DOI: 10.1007/s00296-009-1292-x

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   3.580


  14 in total

1.  Biologic therapy in clinical practice: enthusiasm must be tempered by caution.

Authors:  R Moots; A Taggart; D Walker
Journal:  Rheumatology (Oxford)       Date:  2003-05       Impact factor: 7.580

Review 2.  Side effects of anti-TNF therapy: current knowledge.

Authors:  C Antoni; J Braun
Journal:  Clin Exp Rheumatol       Date:  2002 Nov-Dec       Impact factor: 4.473

Review 3.  New drugs for rheumatoid arthritis.

Authors:  Nancy J Olsen; C Michael Stein
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

Review 4.  Problems encountered during anti-tumour necrosis factor therapy.

Authors:  Sheetal B Desai; Daniel E Furst
Journal:  Best Pract Res Clin Rheumatol       Date:  2006-08       Impact factor: 4.098

Review 5.  Anti-tumour necrosis factor-alpha therapy in heart failure: future directions.

Authors:  Pitchai Balakumar; Manjeet Singh
Journal:  Basic Clin Pharmacol Toxicol       Date:  2006-12       Impact factor: 4.080

Review 6.  Complications and adverse reactions in the use of newer biologic agents.

Authors:  Jeffrey P Callen
Journal:  Semin Cutan Med Surg       Date:  2007-03

Review 7.  Adverse reactions to biologic agents: focus on autoimmune disease therapies.

Authors:  Susan J Lee; Arthur Kavanaugh
Journal:  J Allergy Clin Immunol       Date:  2005-10       Impact factor: 10.793

Review 8.  Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection.

Authors:  Daniel E Furst; Robert Wallis; Michael Broder; David O Beenhouwer
Journal:  Semin Arthritis Rheum       Date:  2006-07-03       Impact factor: 5.532

Review 9.  Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab.

Authors:  Robert S Wallis; Stefan Ehlers
Journal:  Semin Arthritis Rheum       Date:  2005-04       Impact factor: 5.532

Review 10.  Tumour necrosis factor antagonists: structure, function, and tuberculosis risks.

Authors:  Robert S Wallis
Journal:  Lancet Infect Dis       Date:  2008-10       Impact factor: 25.071

View more
  15 in total

Review 1.  Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets.

Authors:  Pauline L Martin; Peter J Bugelski
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 2.  Remicade® (infliximab): 20 years of contributions to science and medicine.

Authors:  Richard Melsheimer; Anja Geldhof; Isabel Apaolaza; Thomas Schaible
Journal:  Biologics       Date:  2019-07-30

3.  Performance evaluation of FlowCytomix assays to quantify cytokines in patients with rheumatoid arthritis.

Authors:  Xuefeng Wang; Liyang Dong; Yong Liang; Hongchang Ni; Jun Tang; Chengcheng Xu; Yuepeng Zhou; Yuting Su; Jun Wang; Deyu Chen; Chaoming Mao
Journal:  Int J Clin Exp Med       Date:  2015-09-15

4.  Prolonged fever after Infliximab infusion.

Authors:  Jennifer Katz; Michael Frank
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-06-06

5.  Mitigation of colitis with NovaSil clay therapy.

Authors:  Katherine E Zychowski; Sarah E Elmore; Kristal A Rychlik; Hoai J Ly; Felipe Pierezan; Anitha Isaiah; Jan S Suchodolski; Aline Rodrigues Hoffmann; Amelia A Romoser; Timothy D Phillips
Journal:  Dig Dis Sci       Date:  2014-09-21       Impact factor: 3.199

6.  Anti-TNF-alpha therapy enhances the effects of enzyme replacement therapy in rats with mucopolysaccharidosis type VI.

Authors:  Efrat Eliyahu; Theodore Wolfson; Yi Ge; Karl J Jepsen; Edward H Schuchman; Calogera M Simonaro
Journal:  PLoS One       Date:  2011-08-22       Impact factor: 3.240

7.  Inhibiting TNF-α signaling does not attenuate induction of endotoxin tolerance.

Authors:  Christopher Loosbroock; Kenneth W Hunter
Journal:  J Inflamm Res       Date:  2014-12-03

8.  Inflammatory arthritis disrupts gut resolution mechanisms, promoting barrier breakdown by Porphyromonas gingivalis.

Authors:  Magdalena B Flak; Romain A Colas; Estefanía Muñoz-Atienza; Michael A Curtis; Jesmond Dalli; Costantino Pitzalis
Journal:  JCI Insight       Date:  2019-07-11

9.  A key regulatory role for Vav1 in controlling lipopolysaccharide endotoxemia via macrophage-derived IL-6.

Authors:  Markus F Neurath; Imke Atreya; Stefanie Zenker; Julia Panteleev-Ivlev; Stefan Wirtz; Tadamitsu Kishimoto; Maximilian J Waldner; Olga Ksionda; Victor L J Tybulewicz
Journal:  J Immunol       Date:  2014-02-14       Impact factor: 5.422

Review 10.  Selective Modulation of TNF-TNFRs Signaling: Insights for Multiple Sclerosis Treatment.

Authors:  Valentina Pegoretti; Wia Baron; Jon D Laman; Ulrich L M Eisel
Journal:  Front Immunol       Date:  2018-04-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.